Lovirab DSR 30mg/40mg Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Esomeprazole 40mg, indicated for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and symptom relief associated with acid-related conditions. The synergistic action of these agents provides comprehensive relief by addressing both motility dysfunction and acid hypersecretion. Lovirab DSR is typically administered orally once daily, preferably before meals, under medical supervision. Caution is advised in patients with hepatic impairment, cardiac arrhythmias, or those taking medications that may interact with Domperidone or Esomeprazole. Common adverse effects may include headache, dry mouth, abdominal discomfort, and dizziness. This combination should be used as prescribed, with adherence to recommended dosing to optimize therapeutic outcomes and minimize potential side effects.